Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Unanswered Questions Spur Future Lung Cancer Research Efforts

January 31st 2023

Edward B. Garon, MD, MS, describes research combining angiogenesis and PD-1/PD-L1 inhibition stemming from the phase 3 IMpower150 trial in patients with metastatic nonsquamous NSCLC.

Therapies Targeting Specific Molecular Alterations in NSCLC

January 31st 2023

A panel of distinguished experts discuss how detection of actionable mutations affect their treatment choices in non-small cell lung cancer.

Adjuvant Therapy in Early Stage NSCLC

January 31st 2023

David Spigel, MD, and David H. Harpole Jr, MD, describe when adjuvant therapy is recommended in early stage NSCLC and discuss data from recent clinical trials of adjuvant therapy.

Cemiplimab Plus Chemotherapy Expands First-Line Options in Advanced NSCLC

January 30th 2023

Ana Baramidze, MD, provides background on the FDA approvals of cemiplimab in NSCLC, expands on key efficacy and safety data with cemiplimab from EMPOWER-Lung 3, and discusses the current treatment landscape for patients with advanced NSCLC.

Dr. de Marinis on the PERLA Trial in Metastatic NSCLC

January 30th 2023

Filippo de Marinis, MD, discusses the goal of the phase 2 PERLA trial in metastatic nonsquamous non–small cell lung cancer, as well as significant results from a primary analysis of this study.

Clinical Insights on the Role of PD-1/PD-L1 Inhibitors in NSCLC

January 30th 2023

Martin Dietrich, MD, PhD, describes his approach to using anti-PD-1 therapies in non–small cell lung cancer.

Applying Molecular Biomarkers in Treatment Decision Making in NSCLC

January 30th 2023

An overview of the prevalence of molecular biomarkers in NSCLC and their effect on treatment decisions.

FDA Approves Adjuvant Pembrolizumab in NSCLC

January 26th 2023

The FDA has approved pembrolizumab (Keytruda) as an adjuvant treatment following resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 cm), II, or IIIA non–small cell lung cancer.

Treatment Approach for Patients With Stage IB Disease

January 24th 2023

A panel of experts in the treatment of NSCLC discusses how they manage patients with stage IB disease.

Workup and Molecular Testing for a Patient with NSCLC

January 24th 2023

David H. Harpole Jr, MD, a thoracic surgeon, details his workup approach and discussed molecular testing for patients who present with NSCLC.

Navigating Barriers to Molecular Testing and Role of Liquid Biopsy in NSCLC

January 23rd 2023

Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.

The Role of Molecular Testing In Metastatic NSCLC

January 23rd 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.

Dy Discusses CEACAM5-Directed and Other Second-Line Treatment Strategies in NSCLC

January 19th 2023

Dr Dy discusses the development of CEACAM5-directed antibody-drug conjugates in non–small cell lung cancer, ongoing research with tusamitamab ravtansine, and the potential role of competing docetaxel-based combination strategies in the second-line setting.

Perioperative Toripalimab Plus Chemotherapy Meets EFS End Point in NSCLC

January 18th 2023

Perioperative treatment with the combination of toripalimab plus platinum-containing doublet chemotherapy, followed by toripalimab monotherapy as consolidation therapy after surgery, significantly extended event-free survival compared with chemotherapy plus placebo in patients with operable NSCLC.

Patient Profile 1: A 57-Year-Old Woman Diagnosed With NSCLC

January 17th 2023

David Spigel, MD, presents a patient case of a 57-year-old woman with NSCLC, and Jaspal Singh, MD, MHS, discusses his approach to initial evaluation.

Multidisciplinary Care in Non-Small Cell Lung Cancer

January 17th 2023

A panel of experts introduce themselves and explain their approaches to multidisciplinary care in treating non-small cell lung cancer.

FDA Grants Orphan Drug Designation to JBI-802 for Small Cell Lung Cancer and AML

January 16th 2023

The FDA has granted an orphan drug designation to JBI-802 for the treatment of patients with small cell lung cancer and acute myeloid leukemia.

Dr. Mercado on Evolution of Biopsy Techniques in Lung Cancer

January 12th 2023

Jorge M. Mercado, MD, discusses the evolution of biopsy techniques in patients with lung cancer.

Dr. Topp on the Safety Profile of Glofitamab Plus R-CHOP in DLBCL

January 12th 2023

Max S. Topp, MD, discusses the safety profile of glofitamab in combination with R-CHOP in patients with diffuse large B-cell lymphoma.

Spira Highlights Key Advancements Across the NSCLC Treatment Paradigm in 2022

January 11th 2023

Alexander Spira, MD, PhD, FACP, highlights the top advancements across non–small cell lung cancer in 2022, emphasized the need for increased genetic testing to inform treatment decisions, and previewed other agents under development.